[F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.
about
Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomasPET and MR imaging: the odd couple or a match made in heaven?Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studiesStaged lengthening arthroplasty for pediatric osteosarcoma around the knee.Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma.A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.Performance of Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Using Fluorine-18-Fluorodeoxyglucose for the Diagnosis, Staging, and Recurrence Assessment of Bone Sarcoma: A Systematic Review and Meta-Analysis.Dynamic contrast-enhanced magnetic resonance imaging as a prognostic factor in predicting event-free and overall survival in pediatric patients with osteosarcoma.Use of Molecular Imaging Markers of Glycolysis, Hypoxia and Proliferation ((18)F-FDG, (64)Cu-ATSM and (18)F-FLT) in a Dog with Fibrosarcoma: The Importance of Individualized Treatment Planning and Monitoring.Imaging pediatric bone sarcomas.Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI.Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcomeIs [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group.Prognostic markers in osteosarcoma.18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different.Clinical applications of positron emission tomography in sarcoma management.Pediatric oncology and the future of oncological imaging.Peritoneal sarcomatosis in pediatric malignancies.The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Assessing the Response to Neoadjuvant Treatment in Patients with Osteosarcoma.Tumor-to-background ratio to predict response to chemotherapy of osteosarcoma better than standard uptake values.Comparison of (18) F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma.How we read pediatric PET/CT: indications and strategies for image acquisition, interpretation and reporting.¹⁸F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma.Metabolic activity measured on PET/CT correlates with clinical outcomes in patients with limb and girdle sarcomas.18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients.Overexpression of hexokinase-2 in giant cell tumor of bone is associated with false positive in bone tumor on FDG-PET/CT.18F-FDG PET/CT compared to conventional imaging modalities in pediatric primary bone tumors.Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma.
P2860
Q26825000-40CA9908-36D0-4B66-80DE-A06A9D131E63Q26851721-D2F37774-AC45-483F-9985-2862685C9602Q33434899-E0C37013-6B70-494C-9F91-AE5F073AF184Q33559468-86259E2C-11B9-420A-AD22-85884555F65EQ33833813-15F472D4-447E-46A3-8A39-8EB869EA5848Q34023973-86410222-68C6-4E33-8BAF-F87B112C3CDDQ34348226-AB8D31FE-F9D9-4465-9E47-D08E210AB614Q34628840-458918DB-8208-41CB-9A65-A542E08EA045Q35769381-CE4B131E-0789-4566-B052-A0FE5629C397Q35848410-DC877445-0954-4A10-8B9C-9D97D2D3645FQ36335296-B340ECB5-E90B-4795-BC49-DAE34BAE5418Q36499007-15205FEB-6102-4D96-86CD-0BB0D7B1DBA8Q36750627-982A0F2E-74A4-4415-8AF2-5BA2576437CEQ37519308-3F78927F-00DE-4B6E-BAD7-7A6454D2283DQ37523470-21D3D1CF-02EC-4C05-AB2A-BB36E1D8FB99Q37560522-0AFBAA14-8E61-4BD0-B88D-227414807D64Q37621398-60C4D971-894A-4432-81E4-C6DBD4BB39C7Q37687395-9A13DEE1-1807-427A-822D-13EA208282B6Q37836534-1A88B219-6F90-491F-B1A2-16921BE24D28Q37845828-439030E9-3AD2-4CA3-A35A-17BEDE7ACA78Q37869417-3450D905-D8BC-40E8-B18E-869CDE7888D8Q38045850-77D8552D-B624-4035-BC66-19D332A219DFQ38046209-72ED9035-B023-4E85-BD77-027D9B91B328Q38217056-9B5B3A46-3935-4D01-80A6-F8E9C3F33111Q41594930-FDA6DA6D-1335-46F4-BC12-620C0D0FD631Q43529305-8CAA47B5-7314-4237-806F-F0AF9BF0D448Q44090756-ADA3B1D2-C1C4-4AAF-9968-E5696DE1A3A5Q44406732-A3CDCDFE-99B3-4845-80E5-0EDA73AA3C3FQ44442401-70061A1C-A3FB-4435-A2E7-FBB8D476B42FQ53150564-F1BE3D32-550E-4430-B5E0-4DAB7434E8E3Q53187964-A57F05AA-8098-4231-9139-0FC15F5B0AD2Q53404618-35D03660-2160-4E7B-B34E-B652D047C714
P2860
[F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
[F-18]-fluorodeoxy-D-glucose-p ...... in children and young adults.
@en
[F-18]-fluorodeoxy-D-glucose-p ...... in children and young adults.
@nl
type
label
[F-18]-fluorodeoxy-D-glucose-p ...... in children and young adults.
@en
[F-18]-fluorodeoxy-D-glucose-p ...... in children and young adults.
@nl
prefLabel
[F-18]-fluorodeoxy-D-glucose-p ...... in children and young adults.
@en
[F-18]-fluorodeoxy-D-glucose-p ...... in children and young adults.
@nl
P2093
P2860
P356
P1433
P1476
[F-18]-fluorodeoxy-D-glucose-p ...... in children and young adults.
@en
P2093
Douglas S Hawkins
Ernest U Conrad
James E Butrynski
Janet F Eary
Scott M Schuetze
P2860
P304
P356
10.1002/CNCR.24421
P407
P577
2009-08-01T00:00:00Z